References
- Weissman MM, Bland RC, Canino GJ et al. Cross-national epidemiology of major depression and bipolar disorder. Journal of the American Medical Association 1996; 276(4): 293–299.
- Attshuler LL, Gitlin MS, Mintz J, Leight KL, Frye MA. Subsyndromal depression is associated with functional impairment in patients with bipolar disorder. Journal of Clinical Psychiatry 2002; 63(9): 807–811.
- Dilsaver DC, Chen YW, Swann AC, Shoaib AM, Tsai-Dilsaver Y, Krajewski RJ. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Research 1997; 73(1-2): 47–56.
- Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 2002; 59(6): 530–537.
- Hlastala SA, Frank E, Mallinger AG, Thase ME, Rifenour AM, Kupfer DJ, Bipolar depression: an underestimated treatment challenge. Depression & Anxiety 1997; 5(2): 73–83.
- Keller MB, Lavori PW, Caryell W et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. Journal of the American Medical Association 1986; 255(22): 3138–3142.
- Bowden CL. Treatment options for bipolar depression. Journal of Clinical Psychiatry 2005; 66 (Suppl 1): 3–6.
- Hirschfeld RM. Guideline watch: practice guideline for the treatment of patients with bipolar disorder, 2nd edition, in http://www.psych.org/psych_ pract/treatg/pg/prac_guide.cfm. 2006, Arlington, VA: American Psychiatric Association.
- Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 2003; 60(11): 1079–1088.
- Keck PE Jr, Corya SA, Altshuler LL et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Journal of Clinical Psychiatry 2005; 66(5): 611–616.
- Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression—lack of manic induction. Journal of Affective Disorders 2005; 87(1): 121–130.
- Shi L, Nanyoshi MA, Swindle R et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clinical Therapeutics 2004; 26(1): 125–134.
- Managed care dossier: Symbyax. Eli Lilly and Company Limited. 2005.
- Strom BL. Pharmacoepidemiology. 4th Edition 2005: John Wiley & Sons.
- Altshuler LL. Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry 1995; 152(8): 1130–1138.
- Leverich GS, Altshuler LL, Suppes T et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. American Journal of Psychiatry 2006; 163(2): 232–239.
- 2002 Guidelines for pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee, in http://www.health.gov.au/internet/wcms/ publishing.nsf/Content/health-pbs-general-pubs-guidelines-index.htm1 (Accessed: September 2006).